Curanex Pharmaceuticals Inc (CURX) company profile
Close on Nov 17, 2026Market cap $7.37MP/E –Yield –
About Curanex Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Curanex Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing botanical medicines for patients with inflammatory diseases. The company's lead drug candidate is Phyto-N, a proprietary botanical extract derived from a medicinal plant used in traditional Chinese medicine. Curanex is advancing a development pipeline targeting six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with its primary development focus on ulcerative colitis.
The company operates as a single corporate entity without subsidiaries and conducts its nonclinical research across partner academic and research institutions. Its planned Phase 1 clinical development is scheduled to take place in Australia following regulatory clearances. Curanex Pharmaceuticals is incorporated in Nevada and maintains its principal executive offices in Jericho, New York.
Summary of the business section of Curanex Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Curanex Pharmaceuticals Inc
- Founded
- 2018
- Headquarters
- Jericho, NY
- Address
- 2 Jericho Plaza,, Suite101b 11753
- Phone
- (718) 673-6078
- Website
- curanexpharma.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Kreit & Chiu CPA LLP, Los Angeles, California
Stock & identifiers
- Ticker
- CURX
- Exchange
- Nasdaq
- IPO date
- Aug 26, 2025
- Shares outstanding
- 31M, Aug 14, 2026
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Aug 20, 2026
- SEC CIK
- 2025942
- FIGI
- BBG01QB818N7
- Share class FIGI
- BBG01QB818P5
- EIN
- 83-0741390
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jun Liu | CEO and President, Director | 10,524,560 |
| Huijuan Zhong | Chief Science Officer, Director | – |
| Ning Zhang | Chief Technology Officer | – |
| Dian Ying Jing | Secretary | 4,651,000 |
| Liqin Xie | Chief Operating Officer | – |
| Xiaohui Hao | Director | – |
| Yong Yan | Director | – |
| Helen Hong Hsu | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 26, 2025
- Offer price
- $4.00
- Securities offered
- 3,750,000
- Gross proceeds
- $15.00M
- Exchange
- Nasdaq
- First trading day
- Aug 26, 2025
- First-day close
- $4.02+0.5%
- Lock-up ends (est.)
- Feb 22, 2026
“Per Share Total Initial public offering price $ 4.00 $ 15,000,000 Underwriting discounts and commissions (1) $ 0.28 $ 1,050,000 Proceeds to us (before expenses) (2) $ 3.72 $ 13,950,000 (1) The Company has agreed to pay the underwriters a fee equal to 7% of the gross proceeds of the offering.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 17, 2025 | Late filing | Notification of late filing |
| Nov 6, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 26, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 25, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?